Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
ABBOTT INDIA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-23 |
TEVA PHARMA Dec-13 |
ABBOTT INDIA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 22,482 | 3,479 | - | |
Low | Rs | 16,156 | 3,022 | - | |
Sales per share (Unadj.) | Rs | 2,517.0 | 1,996.4 | - | |
Earnings per share (Unadj.) | Rs | 446.8 | 124.7 | - | |
Cash flow per share (Unadj.) | Rs | 479.7 | 286.1 | - | |
Dividends per share (Unadj.) | Rs | 325.00 | 109.18 | - | |
Avg Dividend yield | % | 1.7 | 3.4 | 50.1% | |
Book value per share (Unadj.) | Rs | 1,480.5 | 2,217.6 | - | |
Shares outstanding (eoy) | m | 21.25 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.7 | 1.6 | 471.4% | |
Avg P/E ratio | x | 43.2 | 26.1 | 165.9% | |
P/CF ratio (eoy) | x | 40.3 | 11.4 | 354.5% | |
Price / Book Value ratio | x | 13.0 | 1.5 | 890.3% | |
Dividend payout | % | 72.7 | 87.5 | 83.1% | |
Avg Mkt Cap | Rs m | 410,513 | 2,756,220 | 14.9% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 5,636 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,667.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,353.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 53,487 | 1,692,969 | 3.2% | |
Other income | Rs m | 1,543 | 0 | - | |
Total revenues | Rs m | 55,030 | 1,692,969 | 3.3% | |
Gross profit | Rs m | 12,055 | 463,620 | 2.6% | |
Depreciation | Rs m | 700 | 136,844 | 0.5% | |
Interest | Rs m | 160 | 33,253 | 0.5% | |
Profit before tax | Rs m | 12,738 | 293,523 | 4.3% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,682 | -0.0% | |
Tax | Rs m | 3,244 | -3,584 | -90.5% | |
Profit after tax | Rs m | 9,494 | 105,758 | 9.0% | |
Gross profit margin | % | 22.5 | 27.4 | 82.3% | |
Effective tax rate | % | 25.5 | -1.2 | -2,086.0% | |
Net profit margin | % | 17.8 | 6.2 | 284.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 30,251 | 1,143,425 | 2.6% | |
Current liabilities | Rs m | 12,060 | 997,163 | 1.2% | |
Net working cap to sales | % | 34.0 | 8.6 | 393.7% | |
Current ratio | x | 2.5 | 1.1 | 218.7% | |
Inventory Days | Days | 87 | 91 | 95.7% | |
Debtors Days | Days | 2 | 96 | 2.3% | |
Net fixed assets | Rs m | 15,135 | 552,961 | 2.7% | |
Share capital | Rs m | 213 | 4,167 | 5.1% | |
Net worth | Rs m | 31,460 | 1,880,567 | 1.7% | |
Long term debt | Rs m | 0 | 865,653 | 0.0% | |
Total assets | Rs m | 45,386 | 3,868,976 | 1.2% | |
Interest coverage | x | 80.7 | 9.8 | 820.8% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.4 | 269.3% | |
Return on assets | % | 21.3 | 3.6 | 592.0% | |
Return on equity | % | 30.2 | 5.6 | 536.6% | |
Return on capital | % | 41.0 | 4.9 | 831.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,934 | 269,772 | 3.3% | |
From Investments | Rs m | -1,477 | -95,591 | 1.5% | |
From Financial Activity | Rs m | -6,387 | -323,609 | 2.0% | |
Net Cashflow | Rs m | 1,070 | -149,429 | -0.7% |
Compare ABBOTT INDIA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare ABBOTT INDIA With: HESTER BIOSCIENCES CIAN HEALTHCARE AJANTA PHARMA PROCTER & GAMBLE HEALTH LAURUS LABS
Asian stocks fell on Thursday as disappointing earnings forecasts from Facebook parent Meta Platforms hammered tech shares, while the yen's slump past 155 per dollar.